Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy-Reference-Cited by-同舟云学术

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy

Published:2012-11-29 Issue:4 Volume:27 Page:914-924
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Mustjoki S,Auvinen K,Kreutzman A,Rousselot P,Hernesniemi S,Melo T,Lahesmaa-Korpinen A-M,Hautaniemi S,Bouchet S,Molimard M,Smykla R,Lee F Y,Vakkila J,Jalkanen S,Salmi M,Porkka K

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2012348.pdf

Reference50 articles.

1. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417.

2. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251–2259.

3. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260–2270.

4. le Coutre PD, Giles FJ, Hochhaus A, Apperley JF, Ossenkoppele GJ, Blakesley R et al. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 2012; 26: 1189–1194.

5. Shami PJ, Deininger M . Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. Leukemia 2012; 26: 214–224.

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation;Leukemia;2023-11-02

2. Regular Humoral and Cellular Immune Responses in Individuals with Chronic Myeloid Leukemia Who Received a Full Vaccination Schedule against COVID-19;Cancers;2023-10-20

3. Impact of senolytic treatment on immunity, aging, and disease;Frontiers in Aging;2023-10-10

4. In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy;Frontiers in Immunology;2023-09-25

5. Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon‐alpha;British Journal of Haematology;2023-07-22